PET Imaging in Bladder Cancer: An Update and Future Direction.
Jules Zhang-YinAntoine GirardEtienne MarchalThierry LebretMarie Homo SebanMarine UhlMarc BertauxPublished in: Pharmaceuticals (Basel, Switzerland) (2023)
Molecular imaging with positron emission tomography is a powerful tool in bladder cancer management. In this review, we aim to address the current place of the PET imaging in bladder cancer care and offer perspectives on potential future radiopharmaceutical and technological advancements. A special focus is given to the following: the role of [ 18 F] 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in the clinical management of bladder cancer patients, especially for staging and follow-up; treatment guided by [ 18 F]FDG PET/CT; the role of [ 18 F]FDG PET/MRI, the other PET radiopharmaceuticals beyond [ 18 F]FDG, such as [ 68 Ga]- or [ 18 F]-labeled fibroblast activation protein inhibitor; and the application of artificial intelligence.
Keyphrases
- pet imaging
- positron emission tomography
- pet ct
- artificial intelligence
- computed tomography
- machine learning
- current status
- big data
- spinal cord injury
- deep learning
- magnetic resonance imaging
- contrast enhanced
- blood glucose
- lymph node
- type diabetes
- binding protein
- metabolic syndrome
- diffusion weighted imaging
- protein protein
- small molecule
- climate change
- insulin resistance
- adipose tissue
- skeletal muscle
- blood pressure
- wound healing